Travere Therapeutics (NASDAQ:TVTX) currently ticks several boxes for investors who blend high growth momentum criteria with a technical breakout setup. This screen combines three distinct ChartMill ratings—a High Growth Momentum (HGM) score of at least 4, a Technical Analysis (TA) rating above 7, and a Setup Quality rating above 7—to identify stocks that are not only fundamentally accelerating but also exhibiting favorable chart patterns for potential entries. The logic is straightforward: strong earnings and sales momentum paired with a tight consolidation pattern can offer an attractive risk-reward profile for momentum-driven strategies.
High Growth Momentum Rating: Why Travere Stands Out
At the core of this screen is the High Growth Momentum Rating, which evaluates short-term earnings momentum, acceleration, and estimate revisions. Travere scores a 6 out of 10 on this metric, which is considered solid for a stock in the rare disease biotech space. Here’s a breakdown of the key drivers behind that score:
-
Earnings Recovery: Although the trailing twelve-month (TTM) EPS remains negative at -$0.23, the improvement is dramatic. EPS growth over the past TTM year surged 91.8%, while year-over-year comparisons for the last reported quarter showed a 14.9% gain. More notably, the EPS growth in the quarter before last (Q-2) hit a staggering 140%, and the quarter prior (Q-3) came in at 84.6%. This consistent quarter-over-quarter acceleration—despite the negative absolute EPS—signals a company that is quickly narrowing losses and moving toward profitability.
-
Sales Momentum: Revenue growth is equally impressive. The TTM revenue growth rate is 96%, and the most recent quarter posted 55.6% year-over-year sales expansion. Looking back, the prior two quarters (Q-1 and Q-2) delivered 73.4% and 162.1% growth, respectively. This sustained top-line acceleration is a hallmark of high growth momentum.
-
Estimate Beats & Revisions: Travere has beaten EPS estimates in three of the last four quarters, with an average beat of 90.8%. Revenue surprises occurred in two of the last four quarters, averaging 11% above consensus. However, analysts have trimmed their next-year EPS estimates by 16.5% over the past three months, which partly explains why the HGM rating is not higher. Still, the revenue revision trend is slightly positive (+0.5%), suggesting confidence in the top line.
-
Profit Margin Trajectory: While profit margins remain volatile, the most recent quarter showed a slight improvement. After a 15.6% margin two quarters ago, the last quarter dipped to 2.1%, but the overall trend points to margin expansion as revenue scales.
For high growth momentum investors, these metrics matter because they indicate a company that is not just growing but accelerating in key areas. The combination of rapid sales growth, improving earnings, and frequent estimate beats aligns with the CANSLIM and Minervini frameworks, where earnings momentum and surprise factors often precede significant price moves.
Technical Strength: A Perfect Score
Beyond fundamentals, the technical picture is notably strong. Travere earns a perfect 10 out of 10 on the ChartMill Technical Rating, which measures overall technical health by evaluating trends, relative strength, and moving average positioning.
Key technical highlights from the detailed technical report:
- Trend Integrity: Both the short-term and long-term trends are positive. The stock is currently trading above all major moving averages (20-, 50-, 100-, and 200-day), all of which are rising. This alignment is a classic sign of a sustained uptrend.
- Relative Strength: Travere outperforms 98% of all stocks over the past 12 months, and it leads 93% of its peers in the Biotechnology industry. This is a critical filter for momentum investors who seek market leaders.
- Bull Flag Pattern: The stock is currently exhibiting a bull flag formation—a pullback on decreasing volume after a strong upward move. This pattern often precedes a continuation of the trend, offering an entry opportunity near support.
Setup Quality: Ready for a Breakout
The Setup Quality Rating sits at 7 out of 10, indicating a favorable consolidation pattern. The stock has been trading in a tight range, with reduced volatility, while holding above key support zones. The technical report identifies multiple support levels:
- A strong support zone at $56.33, formed by trend lines on both weekly and daily timeframes.
- Additional support at $50.74 and $45.84 from daily trend lines.
- A deeper support at $31.66 from the weekly chart.
The report suggests a potential entry at $56.75 (just above the 10-day moving average) with a stop loss at $56.32, implying a tight 0.75% risk. For a portfolio allocating 25% capital, the total portfolio risk is just 0.19%. While the stop is tight, the pattern’s proximity to support and the strong technical rating make it a setup worth monitoring.
Combining Fundamentals and Technicals
What makes Travere compelling for this screen is the convergence of two forces: the fundamental turnaround story (losses narrowing, revenue surging) and a technically healthy chart with a defined setup. In momentum investing, buying during a consolidation after a strong uptrend reduces the risk of chasing an extended move, while the fundamental acceleration provides the catalyst for the next leg higher.
Want to explore more stocks like this?
Click here to run the full screen and discover other high growth momentum stocks with strong technical breakout setups.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making any trading decisions.
Read full article here »
View the Zacks #1 Rank List
Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup
Travere Therapeutics (NASDAQ:TVTX) currently ticks several boxes for investors who blend high growth momentum criteria with a technical breakout setup. This screen combines three distinct ChartMill ratings—a High Growth Momentum (HGM) score of at least 4, a Technical Analysis (TA) rating above 7, and a Setup Quality rating above 7—to identify stocks that are not only fundamentally accelerating but also exhibiting favorable chart patterns for potential entries. The logic is straightforward: strong earnings and sales momentum paired with a tight consolidation pattern can offer an attractive risk-reward profile for momentum-driven strategies.
High Growth Momentum Rating: Why Travere Stands Out
At the core of this screen is the High Growth Momentum Rating, which evaluates short-term earnings momentum, acceleration, and estimate revisions. Travere scores a 6 out of 10 on this metric, which is considered solid for a stock in the rare disease biotech space. Here’s a breakdown of the key drivers behind that score:
Earnings Recovery: Although the trailing twelve-month (TTM) EPS remains negative at -$0.23, the improvement is dramatic. EPS growth over the past TTM year surged 91.8%, while year-over-year comparisons for the last reported quarter showed a 14.9% gain. More notably, the EPS growth in the quarter before last (Q-2) hit a staggering 140%, and the quarter prior (Q-3) came in at 84.6%. This consistent quarter-over-quarter acceleration—despite the negative absolute EPS—signals a company that is quickly narrowing losses and moving toward profitability.
Sales Momentum: Revenue growth is equally impressive. The TTM revenue growth rate is 96%, and the most recent quarter posted 55.6% year-over-year sales expansion. Looking back, the prior two quarters (Q-1 and Q-2) delivered 73.4% and 162.1% growth, respectively. This sustained top-line acceleration is a hallmark of high growth momentum.
Estimate Beats & Revisions: Travere has beaten EPS estimates in three of the last four quarters, with an average beat of 90.8%. Revenue surprises occurred in two of the last four quarters, averaging 11% above consensus. However, analysts have trimmed their next-year EPS estimates by 16.5% over the past three months, which partly explains why the HGM rating is not higher. Still, the revenue revision trend is slightly positive (+0.5%), suggesting confidence in the top line.
Profit Margin Trajectory: While profit margins remain volatile, the most recent quarter showed a slight improvement. After a 15.6% margin two quarters ago, the last quarter dipped to 2.1%, but the overall trend points to margin expansion as revenue scales.
For high growth momentum investors, these metrics matter because they indicate a company that is not just growing but accelerating in key areas. The combination of rapid sales growth, improving earnings, and frequent estimate beats aligns with the CANSLIM and Minervini frameworks, where earnings momentum and surprise factors often precede significant price moves.
Technical Strength: A Perfect Score
Beyond fundamentals, the technical picture is notably strong. Travere earns a perfect 10 out of 10 on the ChartMill Technical Rating, which measures overall technical health by evaluating trends, relative strength, and moving average positioning.
Key technical highlights from the detailed technical report:
Setup Quality: Ready for a Breakout
The Setup Quality Rating sits at 7 out of 10, indicating a favorable consolidation pattern. The stock has been trading in a tight range, with reduced volatility, while holding above key support zones. The technical report identifies multiple support levels:
The report suggests a potential entry at $56.75 (just above the 10-day moving average) with a stop loss at $56.32, implying a tight 0.75% risk. For a portfolio allocating 25% capital, the total portfolio risk is just 0.19%. While the stop is tight, the pattern’s proximity to support and the strong technical rating make it a setup worth monitoring.
Combining Fundamentals and Technicals
What makes Travere compelling for this screen is the convergence of two forces: the fundamental turnaround story (losses narrowing, revenue surging) and a technically healthy chart with a defined setup. In momentum investing, buying during a consolidation after a strong uptrend reduces the risk of chasing an extended move, while the fundamental acceleration provides the catalyst for the next leg higher.
Want to explore more stocks like this?
Click here to run the full screen and discover other high growth momentum stocks with strong technical breakout setups.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making any trading decisions.
Read full article here »